Call: +919821618106 goral@indonipponivf.com Book an Appointment
Circular teal and navy emblem logo for Indo Nippon IVF Indo Nippon IVF

The Role Of Genetic Screening In Modern IVF Treatments

For many people pursuing IVF, genetic screening can add another layer of information before an embryo is transferred. It may help identify embryos with the expected number of chromosomes, detect specific inherited conditions, or support decisions when there is a known family history of genetic disease. The testing is performed on a small sample of cells taken from an embryo, while the embryo remains in the laboratory.

Genetic testing does not guarantee a pregnancy or a healthy child, and it is not appropriate for every patient. Its value depends on age, medical history, previous treatment outcomes, the number of embryos available, and the reason IVF is being undertaken. Australian patients may also need to consider Medicare arrangements, state-based rules, and the costs of procedures that are not fully covered.

Why Genetic Screening Matters In IVF

An embryo’s genetic material can influence whether it continues developing, implants in the uterus, or results in an early miscarriage. Chromosome differences, known as aneuploidy, become more common as the egg provider’s age increases. Screening may help identify embryos with a chromosome profile more likely to support implantation, although it cannot remove every cause of miscarriage or developmental difficulty.

Pre-implantation genetic testing is often discussed under the broad term “genetic screening”. PGT-A examines chromosome number, while PGT-M looks for a specific single-gene condition, such as cystic fibrosis or Huntington’s disease, when the familial mutation is known. PGT-SR is used in some situations involving structural chromosome rearrangements in a parent.

The purpose of testing should be clearly defined before treatment begins. A patient considering specialist IVF care may benefit from a consultation that connects genetic information with ovarian reserve, sperm health, embryo development and previous pregnancy history. This creates a more realistic treatment plan than treating screening as a stand-alone solution.

What Embryo Testing Can Reveal

In a typical IVF cycle, eggs are collected and fertilised in the laboratory. Embryos are cultured until they reach the blastocyst stage, usually around five or six days after fertilisation. A trained embryologist removes a small number of cells from the outer layer of the blastocyst. The embryo is then frozen while the sample is analysed by a specialised genetics laboratory.

PGT-A can report an embryo as euploid, meaning the tested cells appear to have the expected chromosome number, or aneuploid, meaning a chromosome imbalance was detected. Some results are mosaic, where tested cells show different chromosome patterns. Mosaic findings can be difficult to interpret because the sampled outer cells may not perfectly represent the cells that will form the pregnancy.

PGT-M usually requires considerable preparation. The clinic and genetics team may need to identify the family mutation, design a test for that particular family, and validate it before an IVF cycle starts. PGT-SR may be recommended after recurrent pregnancy loss or when a parent carries a balanced translocation or another chromosome rearrangement.

How Screening Fits Into An IVF Cycle

Genetic screening begins with assessment rather than with the embryo biopsy itself. A fertility specialist may review family history, previous pregnancies, miscarriage patterns, age, ovarian reserve tests and semen analysis. A genetic counsellor can explain inheritance patterns, possible results and whether testing could change the treatment decision.

After ovarian stimulation and egg collection, fertilisation may be completed through conventional IVF or ICSI. ICSI is sometimes selected when sperm-related fertility issues are present or when the laboratory needs to reduce the chance of unexpected sperm contamination during a specific genetic test. It is not automatically required for every patient choosing embryo screening.

Once an embryo is biopsied, there is usually a waiting period for the laboratory report. A frozen embryo transfer is then planned in a later cycle, allowing the uterus to be prepared separately from ovarian stimulation. The transfer may involve hormone replacement or a natural-cycle approach, depending on ovulation and the patient’s clinical circumstances.

Benefits And Limits Of Genetic Screening

For couples carrying a known inherited condition, PGT-M can reduce the chance of transferring an embryo affected by that condition. It may also help families avoid a difficult decision later in pregnancy, although prenatal diagnostic testing is still commonly offered to confirm the result. Genetic counselling is important because reproductive choices are personal and can involve complex ethical considerations.

PGT-A may be useful when there are few embryos and the treatment team is trying to prioritise which one to transfer. In selected patients, it may reduce the number of transfers needed to achieve a pregnancy or lower the chance of transferring an embryo with a major chromosome imbalance. The benefit is less clear for younger patients with a good prognosis and several embryos.

Screening has important limits. It cannot assess every gene, predict a child’s intelligence or personality, or guarantee a pregnancy. The biopsy samples a small part of the embryo, and an embryo labelled euploid may still fail to implant. There can also be no result, an uncertain result, or a mosaic result. These possibilities should be discussed before consent is provided.

Australian Treatment And Cost Considerations

Australian patients often compare care in Sydney, Melbourne, Brisbane, Perth, Adelaide and regional centres before deciding where to have treatment. IVF pricing varies between clinics, and advertised fees may not include medications, anaesthetist charges, laboratory procedures, embryo storage, genetic testing or frozen embryo transfer. Medicare rebates may apply to eligible services, but patients should request an itemised estimate rather than relying on a headline cycle price.

The Medicare Safety Net can affect out-of-pocket spending for some eligible services, while prescription costs and access to subsidised medicines may depend on individual circumstances. Private health insurance may cover parts of hospital-based treatment, but genetic laboratory fees and other services often have separate rules. A clinic’s financial counsellor can explain likely expenses in plain English, which many Australian patients prefer before committing to a cycle.

Regulation also varies across Australia. Assisted reproductive treatment is overseen through national standards and state or territory requirements, with rules affecting donor conception, storage, consent and record keeping. Surrogacy arrangements, for example, are regulated differently in New South Wales, Victoria, Queensland, Western Australia and other jurisdictions. Patients travelling overseas for treatment should confirm how test reports, donor information and follow-up care will be managed after returning home.

For Australians in regional or remote areas, travel to a major fertility centre can add accommodation, time off work and transport costs. Some clinics coordinate telehealth consultations, but blood tests, ultrasounds and procedures still need to be completed at approved locations. Planning these details early can make an IVF cycle less disruptive for FIFO workers, rural families and couples balancing treatment with family responsibilities.

Choosing A Clinic And Understanding Results

A clinic offering genetic testing should explain which laboratory performs the analysis, what type of test is recommended and how results are reported. Patients can ask whether the laboratory is accredited, how samples are tracked, and what happens if an embryo gives a mosaic or inconclusive result. Clear answers are more valuable than broad claims about “advanced technology”.

The specialist team should also explain how the result will affect embryo selection. For example, will a euploid embryo be prioritised over an untested embryo? Will mosaic embryos be considered for transfer, and will a genetic counsellor be involved? Policies can differ between clinics, so patients should understand the local approach before embryos are tested.

The number of embryos available is another important consideration. If only one or two embryos are expected, screening may provide useful information but could leave no embryo suitable for transfer. In other situations, testing may prevent the transfer of embryos unlikely to result in an ongoing pregnancy. The decision should reflect the complete clinical picture, rather than a single test result.

Patients travelling to India or another country for treatment should arrange a record-sharing process with their Australian doctor. Reports should include the test type, laboratory findings, embryo identifiers and recommendations for any pregnancy testing. A local obstetrician or genetic counsellor can then support appropriate prenatal care after a positive pregnancy test.

Practical Points To Discuss Before Testing

A well-prepared appointment can make the decision more manageable. Bring details of previous pregnancies, miscarriages, genetic diagnoses in the family, fertility treatment records and any relevant pathology reports. If a known familial mutation exists, the clinic may need laboratory documentation before an individualised PGT-M test can be designed.

Discuss the likely number of eggs and embryos, the expected timeline, and what will happen if all embryos are abnormal, mosaic or unsuitable for transfer. Ask about the possibility of repeating an IVF cycle, using donor eggs or sperm, or proceeding without embryo testing. These conversations are easier when they happen before stimulation medication is started.

Useful points to raise with the fertility specialist and genetic counsellor include:

Genetic screening works best when it is integrated into broader fertility care. It may support embryo selection and reduce uncertainty for some families, yet it cannot replace careful assessment, evidence-based counselling or routine pregnancy monitoring. A personalised plan should account for emotional wellbeing, financial boundaries, travel requirements and the time involved in treatment.

For patients in Australia considering IVF in India, an early online consultation can clarify whether testing is clinically relevant and how the laboratory process will be coordinated. Contact Indo Nippon IVF to review your fertility history, discuss available genetic testing pathways and develop a treatment plan that supports informed decisions from assessment through embryo transfer.